Pan Deng-Hua, Wen Dong-Yue, Luo Yi-Huan, Chen Gang, Yang Hong, Chen Jun-Qiang, He Yun
Department of Ultrasonography.
Department of Gastrointestinal Surgery.
Onco Targets Ther. 2017 Jul 3;10:3261-3276. doi: 10.2147/OTT.S135593. eCollection 2017.
Growing evidence has demonstrated that Ki-67/MIB-1 has an effect on the clinical progression and prognosis in cancers. However, the diagnostic and prognostic values of Ki-67/MIB-1 in thyroid cancer remain unclear.
The meta-analysis was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies were retrieved from PubMed, EBSCO, EMBASE, ISI Web of Science, China National Knowledge Infrastructure, WanFang and Chinese VIP databases. MetaDiSc and STATA12.0 were used to analyze the meta-analysis. Fixed-effect analysis and random-effect analysis were applied to pool the relative ratio based on heterogeneity in this meta-analysis.
In the meta-analysis, 51 eligible studies were included. The pooled sensitivity of Ki-67/MIB-1 was 0.61 (95% confidence interval [CI]: 0.59-0.63) and specificity was 0.75 (95% CI: 0.74-0.77) in thyroid cancer. The pooled positive likelihood ratio was 3.19 (95% CI: 2.30-4.42) and negative likelihood ratio was 0.43 (95% CI: 0.35-0.54). In the diagnosis of thyroid cancer, the pooled diagnostic odds ratio of Ki-67/MIB-1 was 8.54 (95% CI: 5.03-14.49). The area under the symmetric receiver operating characteristic curve was 0.804 (standard error =0.031). Our results showed that there were statistical associations between Ki-67/MIB-1 and age (odds ratio [OR] =1.71, 95% CI: 1.14-2.57, =0.010), tumor size (OR =1.86, 95% CI: 1.17-2.96, =0.008), lymph node metastasis (OR =2.49, 95% CI: 1.42-4.39, =0.002), metastasis status (OR =6.96, 95% CI: 2.46-19.69, <0.001), tumor node metastasis stage (OR =6.56, 95% CI: 3.80-11.34, <0.001) and extrathyroid extension (OR =1.91, 95% CI: 1.27-2.87, =0.002). Furthermore, thyroid cancer patients with a high level of Ki-67/MIB-1 had a worse disease-free survival as compared to patients with a low level of Ki-67/MIB-1 (hazard ratio =5.19, 95% CI: 3.18-8.46, <0.001). Also, Ki-67/MIB-1 was found to be associated with increased risk of mortality (hazard ratio =3.56, 95% CI: 1.17-10.83, =0.025).
Our results demonstrated that Ki-67/MIB-1 might act as a potential factor in diagnosing thyroid cancer in Chinese. Also, the meta-analysis indicated that Ki-67/MIB-1 might have an effect on prognosis in non-Chinese thyroid cancer patients.
越来越多的证据表明,Ki-67/MIB-1对癌症的临床进展和预后有影响。然而,Ki-67/MIB-1在甲状腺癌中的诊断和预后价值仍不清楚。
按照系统评价和Meta分析的首选报告项目指南进行Meta分析。从PubMed、EBSCO、EMBASE、ISI Web of Science、中国知网、万方和维普数据库中检索研究。使用MetaDiSc和STATA12.0进行Meta分析。本Meta分析基于异质性采用固定效应分析和随机效应分析来汇总相对比值。
在Meta分析中,纳入了51项符合条件的研究。在甲状腺癌中,Ki-67/MIB-1的合并敏感度为0.61(95%置信区间[CI]:0.59 - 0.63),特异度为0.75(95%CI:0.74 - 0.77)。合并阳性似然比为3.19(95%CI:2.30 - 4.42),阴性似然比为0.43(95%CI:0.35 - 0.54)。在甲状腺癌诊断中,Ki-67/MIB-1的合并诊断比值比为8.54(95%CI:5.03 - 14.49)。对称受试者工作特征曲线下面积为0.804(标准误 = 0.031)。我们的结果表明,Ki-67/MIB-与其与年龄(比值比[OR] = 1.71,95%CI:1.14 - 2.57,P = 0.010)、肿瘤大小(OR = 1.86,95%CI:1.17 - 2.96,P = 0.008)、淋巴结转移(OR = 2.49,95%CI:1.42 - 4.39,P = 0.002)、转移状态(OR = 6.96,95%CI:2.46 - 19.69,P < 0.001)、肿瘤-淋巴结-转移分期(OR = 6.56,95%CI:3.80 - 11.34,P < 0.001)和甲状腺外侵犯(OR = 1.91,95%CI:1.27 - 2.87,P = 0.002)之间存在统计学关联。此外,与Ki-67/MIB-1水平低的患者相比,Ki-67/MIB-1水平高的甲状腺癌患者无病生存期更差(风险比 = 5.19,95%CI:3.18 - 8.46,P < 0.001)。而且,发现Ki-67/MIB-1与死亡风险增加相关(风险比 = 3.56,95%CI:1.17 - 10.83,P = 0.025)。
我们的结果表明,Ki-67/MIB-1可能是中国人群甲状腺癌诊断的潜在因素。此外,Meta分析表明,Ki-67/MIB-1可能对非中国甲状腺癌患者的预后有影响。